Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products through acquisitions or licensing. Their commercial capabilities include marketing via sales force and non-personal promotion, market access through payor contracting, and trade and distribution. Key products include ROLVEDON (eflapegrastim-xnst) injection, INDOCIN (indomethacin) Suppositories and Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution), and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN products are NSAIDs. We show 28 historical shares outstanding datapoints in our ASRT shares outstanding history coverage, used to compute ASRT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ASRT market cap history over the course of time is important for investors
interested in comparing ASRT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ASRT versus a peer is one thing; comparing
ASRT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ASRT can fluctuate over the course of history.
With this page we aim to empower investors researching ASRT by allowing them to research the ASRT market cap history. |
Free ASRT Email Alerts:
Video: The Importance of Market Cap
